Surmodics (NASDAQ:SRDX - Get Free Report)'s stock had its "hold" rating restated by analysts at Needham & Company LLC in a report released on Wednesday,Benzinga reports.
A number of other equities analysts have also commented on SRDX. StockNews.com initiated coverage on shares of Surmodics in a research report on Monday, February 3rd. They set a "hold" rating on the stock. Lake Street Capital upgraded shares of Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price target for the company in a research report on Friday, March 7th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $43.00.
View Our Latest Report on Surmodics
Surmodics Stock Performance
Shares of SRDX stock traded down $0.56 during trading on Wednesday, reaching $27.08. 26,143 shares of the company's stock were exchanged, compared to its average volume of 277,211. The company has a quick ratio of 4.29, a current ratio of 5.45 and a debt-to-equity ratio of 0.26. The firm's fifty day moving average price is $29.43 and its 200-day moving average price is $34.86. Surmodics has a twelve month low of $26.00 and a twelve month high of $42.44. The stock has a market capitalization of $387.22 million, a PE ratio of -26.77 and a beta of 1.32.
Surmodics (NASDAQ:SRDX - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.07). The company had revenue of $28.09 million for the quarter, compared to the consensus estimate of $32.23 million. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. As a group, sell-side analysts anticipate that Surmodics will post 0.2 EPS for the current year.
Hedge Funds Weigh In On Surmodics
Several hedge funds have recently bought and sold shares of SRDX. Modus Advisors LLC acquired a new position in Surmodics during the fourth quarter worth about $40,000. R Squared Ltd bought a new position in shares of Surmodics in the 4th quarter valued at $55,000. Legal & General Group Plc boosted its holdings in shares of Surmodics by 34.2% during the 4th quarter. Legal & General Group Plc now owns 3,452 shares of the company's stock valued at $137,000 after acquiring an additional 880 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in Surmodics during the 4th quarter worth $217,000. Finally, Polymer Capital Management US LLC bought a new position in Surmodics in the fourth quarter valued at about $255,000. 96.63% of the stock is owned by institutional investors.
About Surmodics
(
Get Free Report)
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
Featured Articles
Before you consider Surmodics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surmodics wasn't on the list.
While Surmodics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
